Controlled Comparison of Two Moxifloxacin Containing Treatment Shortening Regimens in Pulmonary Tuberculosis
Status:
Completed
Trial end date:
2014-02-01
Target enrollment:
Participant gender:
Summary
REMoxTB is a study for the "Rapid Evaluation of Moxifloxacin in the treatment of sputum smear
positive tuberculosis". REMoxTB aims to find and evaluate new drugs and regimens that shorten
the duration of tuberculosis therapy.
The purpose of REMoxTB is to evaluate the efficacy, safety and acceptability of two
moxifloxacin-containing treatment combinations to determine whether substituting ethambutol
with moxifloxacin in one combination, and/or substituting isoniazid with moxifloxacin in
another combination, makes it possible to reduce the duration of treatment for TB.
Phase:
Phase 3
Details
Lead Sponsor:
Global Alliance for TB Drug Development
Collaborators:
Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma European and Developing Countries Clinical Trials Partnership (EDCTP) Sanofi University College, London